Cargando…

Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma

As the first oral multi-target anti-tumor drug proved for the treatment of patients with advanced liver cancer in 2007, sorafenib has changed the landscape of advanced hepatocellular carcinoma (HCC) treatment. However, drug resistance largely hinders its clinical application. Non-coding RNAs (ncRNAs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Yongting, Feng, Bing, Abudoureyimu, Mubalake, Zhi, Yingru, Zhou, Hao, Wang, Ting, Chu, Xiaoyuan, Chen, Ping, Wang, Rui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848262/ https://www.ncbi.nlm.nih.gov/pubmed/31750247 http://dx.doi.org/10.3389/fonc.2019.01156

Ejemplares similares

Corrigendum: Non-coding RNAs: Emerging Regulators of Sorafenib Resistance in Hepatocellular Carcinoma
por: Lai, Yongting, et al.
Publicado: (2020)

FOXM1-Mediated LINC-ROR Regulates the Proliferation and Sensitivity to Sorafenib in Hepatocellular Carcinoma
por: Zhi, Yingru, et al.
Publicado: (2019)

Recent progress in the emerging role of exosome in hepatocellular carcinoma
por: Abudoureyimu, Mubalake, et al.
Publicado: (2018)

Corrigendum: Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2020)

Oncolytic Adenovirus—A Nova for Gene-Targeted Oncolytic Viral Therapy in HCC
por: Abudoureyimu, Mubalake, et al.
Publicado: (2019)

Targeting Long Non-Coding RNAs in Hepatocellular Carcinoma: Progress and Prospects
por: Lin, Xinrong, et al.
Publicado: (2021)

Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression
por: Tian, Chuan, et al.
Publicado: (2021)

Correction to: Linc-ROR facilitates progression and angiogenesis of hepatocellular carcinoma by modulating DEPDC1 expression
por: Tian, Chuan, et al.
Publicado: (2021)

The Role of Non-Coding RNAs in the Sorafenib Resistance of Hepatocellular Carcinoma
por: Hu, Xinyao, et al.
Publicado: (2021)

The Potential Roles of Exosomal Non-Coding RNAs in Hepatocellular Carcinoma
por: Wang, Wei, et al.
Publicado: (2022)

A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma
por: Zhang, Kai, et al.
Publicado: (2018)

Insights Into circRNAs: Functional Roles in Lung Cancer Management and the Potential Mechanisms
por: Feng, Bing, et al.
Publicado: (2021)

PU.1/microRNA-142-3p targets ATG5/ATG16L1 to inactivate autophagy and sensitize hepatocellular carcinoma cells to sorafenib
por: Zhang, Kai, et al.
Publicado: (2018)

Camrelizumab Plus Sorafenib Versus Sorafenib Monotherapy for Advanced Hepatocellular Carcinoma: A Retrospective Analysis
por: Liu, Qinqin, et al.
Publicado: (2021)

Exosomal Non-Coding RNAs: Regulatory and Therapeutic Target of Hepatocellular Carcinoma
por: Xia, Haoming, et al.
Publicado: (2021)

Effect of the Hypoxia Inducible Factor on Sorafenib Resistance of Hepatocellular Carcinoma
por: Zeng, Zhi, et al.
Publicado: (2021)

Nivolumab Versus Regorafenib in Patients With Hepatocellular Carcinoma After Sorafenib Failure
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Emerging role of non-coding RNAs in glucose metabolic reprogramming and chemoresistance in colorectal cancer
por: Yan, Shushan, et al.
Publicado: (2022)

Improving the Therapeutic Efficacy of Sorafenib for Hepatocellular Carcinoma by Repurposing Disulfiram
por: Zhang, Gong, et al.
Publicado: (2022)

Deep Learning Predicts Overall Survival of Patients With Unresectable Hepatocellular Carcinoma Treated by Transarterial Chemoembolization Plus Sorafenib
por: Zhang, Lei, et al.
Publicado: (2020)

The Impact of Long Non-Coding RNAs in the Pathogenesis of Hepatocellular Carcinoma
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Prognostic Performance of Albumin–Bilirubin Grade With Artificial Intelligence for Hepatocellular Carcinoma Treated With Transarterial Chemoembolization Combined With Sorafenib
por: Zhong, Bin-Yan, et al.
Publicado: (2020)

Circular RNAs in Hepatocellular Carcinoma: Emerging Functions to Clinical Significances
por: Zhang, Yucheng, et al.
Publicado: (2021)

Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, Fluorouracil, and Leucovorin With or Without Sorafenib as Initial Treatment for Advanced Hepatocellular Carcinoma
por: Liang, Run-Bin, et al.
Publicado: (2021)

The Ribosomal Protein L28 Gene Induces Sorafenib Resistance in Hepatocellular Carcinoma
por: Shi, Yi, et al.
Publicado: (2021)

The Emerging Landscape of Long Non-Coding RNAs in Colorectal Cancer Metastasis
por: Liao, Zhiming, et al.
Publicado: (2021)

Emerging Role of Long Non-Coding RNAs in the Pathobiology of Glioblastoma
por: Rezaei, Omidvar, et al.
Publicado: (2021)

The Emerging Landscape of Long Non-Coding RNAs in Wilms Tumor
por: Liu, Qiang
Publicado: (2022)

Survival and adverse events of elderly patients treated with sorafenib for hepatocellular carcinoma
por: Soria, Anna, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Hepatic Arterial Infusion of FOLFOX Combined Sorafenib for Advanced Hepatocellular Carcinoma With Portal Vein Invasion
por: Li, Meiyue, et al.
Publicado: (2021)

Non-coding RNAs as emerging regulators of epithelial to mesenchymal transition in non-small cell lung cancer
por: Chen, Ying, et al.
Publicado: (2017)

Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
por: Luo, Ya, et al.
Publicado: (2020)

Development of an Aerobic Glycolysis Index for Predicting the Sorafenib Sensitivity and Prognosis of Hepatocellular Carcinoma
por: Pan, Yu, et al.
Publicado: (2021)

Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Efficacy and safety of transarterial chemoembolization plus sorafenib in patients with recurrent hepatocellular carcinoma after liver transplantation
por: Zhang, Xia, et al.
Publicado: (2023)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

Resection vs. Sorafenib for Hepatocellular Carcinoma With Macroscopic Vascular Invasion: A Real World, Propensity Score Matched Analytic Study
por: Mei, Jie, et al.
Publicado: (2020)

Designer Exosomes for Targeted Delivery of a Novel Therapeutic Cargo to Enhance Sorafenib-Mediated Ferroptosis in Hepatocellular Carcinoma
por: Li, Xiaoju, et al.
Publicado: (2022)

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kuo, Yuan-Hung, et al.
Publicado: (2021)

Safety and Efficacy of Transcatheter Arterial Chemoembolization Plus Radiotherapy Combined With Sorafenib in Hepatocellular Carcinoma Showing Macrovascular Invasion
por: Zhao, Yuting, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fjjb3glbtjjpeg1ddrjnli6tnj